

**Final Agenda**  
**68<sup>th</sup> meeting of the Committee for Risk Assessment**  
**(RAC-68)**  
**11-14 March 2024**

**Face-to-face/Hybrid meeting\***

**Monday, 11 March starts at 10.00**  
**Thursday, 14 March ends at 18.20**

***Times are Helsinki times***

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/68/2024***

***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

- 4.1 Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

***For agreement***

***Closed session***

**Item 5 – Work plan**

- 5.1 RAC Work Plan for all processes

***For information***

**Item 6 – Requests under Article 77(3)(c)**

- 6.1 Request to review the CLH Opinion on Lithium carbonate (LiCO<sub>3</sub>), lithium chloride (LiCl), lithium hydroxide (LiOH)

- 6.2 Request to review the CLH Opinion on Methyl methacrylate (MMA)

***For adoption***

---

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.

## Item 7 – Health based exposure limits at the workplace

### 7.1 Opinions for discussion

- 1,3-Butadiene (EC number: 203-450-8; CAS RN: 106-99-0)
- Boron and its compounds (EC numbers: 233-139-2, 215-575-5, 215-540-4, 215-125-8 and CAS RN: 10043-35-3, 1332-77-0, 1330-43-4, 1303-86-2 respectively)

***For discussion***

## Item 8 – Harmonised classification and labelling (CLH)

### 8.1 General CLH issues

- Renewal of the RAC CLH WG mandate
- Report from the January CLH Working Group

***For agreement  
RAC/68/2024/01***

***For information  
RAC/68/2024/02***

### 8.2 CLH dossiers

#### 1. Hazard classes for agreement without plenary debate (A-list)

- **Pyriproxyfen (ISO):** *all hazard classes, except for aquatic chronic toxicity*
- **Undecafluorohexanoic acid, PFHxA [1]; sodium undecafluorohexanoate, NaPFHx [2]; ammonium undecafluorohexanoate, APFHx [3]; other inorganic salts of undecafluorohexanoic acid [4]:** *STOT RE, reproductive toxicity (fertility and lactation)*
- **Benzobicyclon (ISO):** *all hazard classes*
- **Sodium bromide:** *STOT SE, STOT RE (nervous system and adrenals)*
- **Potassium bromide:** *STOT SE, STOT RE (nervous system and adrenals)*
- **Calcium bromide:** *STOT SE, STOT RE (nervous system and adrenals)*
- **1-amino-4-hydroxy-2-phenoxyanthraquinone:** *skin sensitisation*
- **Dimethachlor (ISO):** *all hazard classes, except for carcinogenicity*

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.

## 2. Hazard classes for agreement with plenary debate

1. **Metyltetraprole (ISO); 1-[2-({[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}methyl)-3-methylphenyl]-4-methyl-1,4-dihydro-5H-tetrazol-5-one (EC - ; CAS 1472649-01-6) (EC - ; CAS 1472649-01-6):**  
*carcinogenicity*
2. **Pyriproxyfen (ISO); 2-(1-methyl-2-(4-phenoxyphenoxy)ethoxy)pyridine; 4-phenoxyphenyl (RS)-2-(2-pyridyloxy) propyl ether (EC 429-800-1; CAS 95737-68-1):**  
*aquatic chronic toxicity*
3. **Calcium tetraborate (EC 234-511-7; CAS 12007-56-6):**  
*reproductive toxicity*
4. **Calcium metaborate (Ca(BO<sub>2</sub>)<sub>2</sub>) and calcium tetraborate (CaB<sub>4</sub>O<sub>7</sub>), amorphous reaction products of boric acid with lime (EC -; CAS -):**  
*reproductive toxicity*
5. **Pentaboron sodium octaoxide (EC 234-522-7; CAS 12007-92-0):**  
*reproductive toxicity*
6. **Sodium metaborate, anhydrous [1]; boric acid (HBO<sub>2</sub>), sodium salt, tetrahydrate [2]; and any other hydrated form (EC 231-891-6 [1]; - [2]; CAS 7775-19-1 [1]; 10555-76-7 [2]):**  
*reproductive toxicity*
7. **Diammonium decaborate (EC 234-521-1; CAS 12007-89-5) :**  
*reproductive toxicity*
8. **Potassium metaborate (EC 237-262-2; CAS 13709-94-9):**  
*reproductive toxicity*
9. **Dipotassium tetraborate (EC 215-575-5; CAS 1332-77-0):**  
*reproductive toxicity*
10. **Magnesium metaborate (EC 237-235-5; CAS 13703-82-7):**  
*reproductive toxicity*
11. **Dipotassium octaborate (EC - ; CAS 12008-39-8):**  
*reproductive toxicity*
12. **Potassium pentaborate (EC 234-371-7; CAS 11128-29-3):**  
*reproductive toxicity*
13. **Undecafluorohexanoic acid, PFHxA [1]; sodium undecafluorohexanoate, NaPFHx [2]; ammonium undecafluorohexanoate, APFHx [3]; other inorganic salts of undecafluorohexanoic acid [4] (EC 206-196-6[1]; 220-881-7[2]; 244-479-6[3]; - [4] ; CAS 307-24-4[1]; 2923-26-4[2]; 21615-47-4[3]; - [4]):**  
*reproductive toxicity (development)*
14. **Sodium bromide (EC 231-599-9; CAS 7647-15-6):**  
*reproductive toxicity, STOT RE (thyroid)*
15. **Potassium bromide (EC 231-830-3; CAS 7758-02-3):**  
*reproductive toxicity, STOT RE (thyroid)*
16. **Calcium bromide (EC 232-164-6; CAS 7789-41-5):**  
*reproductive toxicity, STOT RE (thyroid)*
17. **Dimethachlor (ISO); 2-chloro-N-(2,6-dimethylphenyl)-N-(2-methoxyethyl)acetamide (EC 256-625-6; CAS 50563-36-5):**  
*carcinogenicity*

**For discussion and adoption**

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.

## **Item 9 – Restrictions**

### **9.1 General restriction issues**

1. Renewal of the RAC REST WG mandate

***For agreement  
RAC/68/2024/01***

2. Report from the March REST Working Group

***For information***

### **9.2 Restriction Annex XV dossiers**

1. Opinion development

1. Universal per- and polyfluoroalkyl substances (UPFAS) – Overview on next plenary discussions and Draft opinion with focus on hazard, consumer mixtures, cosmetics, ski wax

***For discussion***

## **Item 10 – Authorisation**

### **10.1 General authorisation issues**

1. Renewal of the RAC AFA WG mandate

***For agreement  
RAC/68/2024/01***

2. Report from the February AFA Working Group

***For information  
RAC/68/2024/03***

3. Update on incoming/future applications and horizontal issues

***For discussion/agreement  
RAC/68/2024/04***

### **10.2 Authorisation applications**

#### **1. Discussion on key issues**

1. 348\_RR1\_NPE\_Chemetall (2 uses)
2. 349\_RR1\_OPE\_Biomerieux (1 use)
3. 350\_RR1\_OPE\_PPG (2 uses)
4. 351\_PD\_Turdus (1 use)
5. 352\_DEHP\_Baxter (3 uses)
6. 353\_TEL\_Shell (1 use)

***For information***

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

### **10.3 Agreement on draft opinions**

#### **1. Draft opinions for agreement without plenary debate (A-list)**

1. 346\_CT\_Safran\_landing\_systems (2 uses)

***For agreement***

#### **2. Draft opinions for agreement with plenary debate**

1. 325\_ADCR\_Anodise\_sealing (1 use)
2. 326\_ADCR\_Anodising (1 use)
3. 327\_ADCR\_Chemical\_conversion\_coating (1 use)
4. 328\_ADCR\_Chromate\_rinsing (1 use)
5. 329\_ADCR\_Electroplating (1 use)
6. 330\_ADCR\_Finish\_stripping (1 use)
7. 331\_ADCR\_Formulation (1 use)
8. 332\_ADCR\_Passivation\_metallic\_coatings (1 use)
9. 333\_ADCR\_Pre-treatments (1 use)
10. 334\_ADCR\_Stainless\_steel\_passivation (1 use)
11. 335\_ADCR\_RR\_Anodising (1 use)
12. 336\_ADCR\_RR\_Anodise\_sealing (1 use)
13. 337\_ADCR\_RR\_Chemical\_conversion\_coating (1 use)
14. 338\_ADCR\_RR\_Chromate\_rinsing (1 use)
15. 339\_ADCR\_RR\_Electroplating (1 use)
16. 340\_ADCR\_RR\_Finish\_stripping (1 use)
17. 341\_ADCR\_RR\_Formulation (1 use)
18. 342\_ADCR\_RR\_Passivation\_metallic\_coatings (1 use)
19. 343\_ADCR\_RR\_Pre-treatments (1 use)
20. 344\_ADCR\_RR\_Slurry\_coating (1 use)
21. 345\_ADCR\_RR\_Stainless\_steel\_passivation (1 use)
22. 347\_CT\_Safran\_Aircraft\_Engines (1 use)

***For discussion and agreement***

### **10.4 Adoption of opinions**

1. 305\_CT\_Meoni\_e\_Bartoletti (1 use)
2. 310\_CT\_Cromotecnica\_Fida (1 use)

***For discussion and adoption***

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

## **Item 11 – Drinking Water Directive**

11.1 Renewal of the RAC DWD WG mandate

***For agreement***  
***RAC/68/2024/01***

11.2 Final Draft Agenda for the 3rd Meeting of the Committee for Risk Assessment DWD Working Group reporting to RAC-68 (RAC WG/A/3/2024) - Common Session with RAC-68 and RAC-68 DWD WG on Thursday 14 March PM

***For adoption***  
***RAC/68/2024/05***

11.3 Update on the adoption of the DWD implementing legislation

11.4 Case Study 1: Starting substance: Introduction

11.5 Case Study 2: Metallic composition: Introduction

11.6 Proposal for a support group on toxicokinetics for DWD guidance

***For information/discussion***

## **Item 12 – AOB**

## **Item 13 – Minutes of RAC-68**

1. Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-68

***For adoption***

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*